MedTrace Logo

Urine CXCL10 Chemokine Monitoring Post-renal Transplant

NCT03140514 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 241

Last updated 2022-08-11

No results posted yet for this study

Summary

In this study investigators will investigate whether early treatment of allograft rejection, as detected by urine CXCL10-monitoring, improves outcomes in renal allograft recipients.

Conditions

  • Renal Transplant Rejection

Interventions

DRUG

Rejection treatment according to clinical standard-of-care

Standard-of-care treatment is based on the severity and phenotype of biopsy-proven rejection

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Stefan Schaub, MD, MSc · University Hospital, Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-28
Primary Completion
2022-07-15
Completion
2022-07-15

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03140514 on ClinicalTrials.gov